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Sir,
We read with interest the short communication by Di Fiore
et al (2011), reporting the correlation between survival and
grade 3–4 toxicities in advanced renal cancer patients treated
with tyrosine kinase inhibitors (TKIs). As it had been done
previously in intestinal stromal digestive, renal, lung and colorectal
cancer treated with anti-target drugs, there seems to exist a direct
relation between the development of mechanism-based toxicities
as rash, hypertension, hypothyroidism and the response to the
treatment (Dienstmann et al, 2011). The authors evaluated
retrospectively 38 patients treated with sunitinib and sorafenib.
They evaluated predictive and prognostic factors related to
survival, suggesting that grade 3–4 clinical TKI-related toxicities
(digestive, cardiac, dermatologic and asthenia) are associated with
a significant improvement (grade 1–2 vs 3–4 HR 5.55 (CI 95%
1.23–24.9) of overall survival.
In relation to the work presented, we have done a prospective
evaluation of 40 advanced hepatocellular carcinoma patients
treated with sorafenib between 2002 and 2011 in our centre.
In our work, we looked for prognosis and predictive factors of
response to sorafenib. We analysed epidemiological factors,
previous treatments, comorbidity, performance status and the
origin of the hepatic disease. The patients received sorafenib
(400mg twice a day; Llovet et al, 2008) and during the treatment,
toxicity (CTCAE 4.3, 2010) and response were monitorised.
In all, 82% of patients were men, with a medium age of 67 years
(range 40–82). In all, 92% of patients were Child A, and 82.5%
were BCLC-C. Chronic hepatitis C virus infection was the
predominant cause of liver disease (40%), followed by alcohol
consumption (20%). The mean number of cycles of sorafenib
administrated was 4 (understanding a cycle of treatment as 28 days
without discontinuation; range 1–24). According to RECIST
criteria v.1.1, the disease control rate was 25% (CI 95% 17–35;
22.5% disease stabilisation and 2.5% partial response), with a
progression-free survival of 19.7 weeks (CI 95% 9.8–29.58) and an
overall survival of 24.1 weeks (CI 95% 6.09–42.19). These results
were similar to those obtained in the SHARP trial (Llovet et al,
2008). Nine patients (22%) developed grade 3–4 toxicity: three
(7.5%) diarrhoea, two (5%) asthenia and four (10%) hand-foot
syndrome. Looking for prognostic factors, our results suggest that
there is a significant improvement of progression-free survival
(P¼ 0.05) for those patients who develop severe skin toxicity.
Clearly, our results are going in the same direction as Di Fiore
et al (2011). We also agree with the authors that toxicity could
be linked to efficacy; however, this has not been shown in early
drug development (Postel-Vinay et al, 2009). The authors of this
later report did not find any correlation between the efficacy and
the dose received by patients in targeted agent phase I trials.
This later aspect could underline the importance of long-term
and cumulative toxicities, which are not well studied in classical
phase I trials.
The increasing amount of evidence about the linkage between
toxicity and efficacy needs to be tested in randomised trials.
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